🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Ken Fisher’s TRAX Holdings & Trades

First Buy
Q2 2026
Duration Held
1 Quarters
Largest Add
Q2 2026
+51,549 Shares
Current Position
51,549 Shares
$1.04 M Value

Ken Fisher's TRAX Position Overview

Ken Fisher (via Fisher Asset Management, LLC) currently holds 51,549 shares of First Tracks Biotherapeutics, Inc. (TRAX) worth $1.04 M, representing 0.00% of the portfolio. First purchased in 2026-Q2, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Ken Fisher has initiated a new position in TRAX, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Ken Fisher's First Tracks Biotherapeutics (TRAX) Holding Value Over Time

Track share changes against reported price movement

Quarterly First Tracks Biotherapeutics (TRAX) Trades by Ken Fisher

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q2 2026 +51,549 New Buy 51,549 $20.12

Ken Fisher's First Tracks Biotherapeutics Investment FAQs

Ken Fisher first purchased First Tracks Biotherapeutics, Inc. (TRAX) in Q2 2026, acquiring 51,549 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Ken Fisher has held First Tracks Biotherapeutics, Inc. (TRAX) for 1 quarters since Q2 2026.

Ken Fisher's largest addition to First Tracks Biotherapeutics, Inc. (TRAX) was in Q2 2026, adding 51,549 shares worth $1.04 M.

According to the latest 13F filing for Q2 2026, Ken Fisher's firm, Fisher Asset Management, LLC, owns 51,549 shares of First Tracks Biotherapeutics, Inc. (TRAX), valued at approximately $1.04 M.

As of the Q2 2026 filing, First Tracks Biotherapeutics, Inc. (TRAX) represents approximately 0.00% of Ken Fisher's publicly disclosed stock portfolio, making it one of their key holdings.

Ken Fisher's peak holding in First Tracks Biotherapeutics, Inc. (TRAX) was 51,549 shares, as reported at the end of Q2 2026.